Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
(7h)
Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally
(8h)
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
(8h)
Merck teams up with British medtech to boost vaginal therapeutics delivery system
(11h)
AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial
(13h)
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
(23h)
OrsoBio hits target in midstage study for metabolic conditions but stays silent on details
(1d)
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
(1d)
Bristol Myers and Evinova pen global development partnership
(1d)
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
(1d)
FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils
(1d)
Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial
(1d)
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
(1d)
Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics
(4d)
ILiAD Biotechnologies snags $115M series B for whooping cough vaccine
(4d)
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
(4d)
CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech
(4d)
UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge
(4d)
Qiagen 'open for discussion' on shareholder value, but CEO stays mum on takeover talk
(4d)
Agomab, SpyGlass head to Nasdaq with IPOs totalling $350M
(4d)
BioPharma Dive
Novo combination obesity shot meets goal in diabetes trial
(1w)
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
(1w)
GSK walks away from pioneering Wave RNA editing drug
(1w)
Building a robust in-process testing plan for cell therapy manufacturing success
(1w)
Amgen gives up on its once-prized eczema drug
(2w)
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
(2w)
Politicization runs deeper than ever at FDA, risking long-term impacts
(2w)
The biopharma industry outlook on 2026: Optimism and tension
(2w)
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
(2w)
AstraZeneca strengthens China ties with planned $15B investment
(2w)
Moderna holds a ‘garage sale’; Roche defends obesity drug data
(2w)
Tenpoint wins FDA nod for combination presbyopia eye drop
(2w)
Lilly bets on Seamless, delving further into genetic medicine for hearing loss
(2w)
Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
(2w)
Halozyme buys a biotech startup; Cytokinetics launches heart drug
(2w)
Regenxbio gene therapy trials suspended by FDA over safety worries
(2w)
FDA lifts hold on an Intellia CRISPR drug trial
(2w)
Roche, trailing in obesity, showcases new data for GLP-1 shot
(2w)
An immune drug developer raises $50M to finance its eczema drug testing
(2w)
China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
(2w)
Endpoints News
Isomorphic claims major advance with new AI drug design engine
(2h)
ILiAD raises $115M round to advance whooping cough vaccine
(2h)
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
(2h)
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
(3h)
Is AstraZeneca on track to meet its $80B revenue target?
(6h)
The fallout from Novo vs. Hims
(7h)
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
(7h)
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
(7h)
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
(10h)
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
(10h)
'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
(11h)
Hengrui, Kailera push obesity pill ahead on promising mid-stage China data
(11h)
FDA rejects Regenxbio's Hunter syndrome gene therapy
(1d)
With scant data, RFK Jr. credits Trump for higher European drug prices
(1d)
QuantX raises $85M Series B from Lilly, Sanofi Ventures
(1d)
Despite FDA’s crackdown, pharma is still spending millions on ads
(1d)
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
(1d)
Galux raises $29M Series B; CSL teams up with Memo
(1d)
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
(1d)
Takeda, Iambic sign multiyear R&D deal for AI drug discovery
(1d)
BioSpace
Webinar: 2026 Hiring Trends and Job Market Signals
(1h)
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
(7h)
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
(9h)
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
(9h)
REGENXBIO’s Hunter Syndrome Gene Therapy Fails to Win FDA Nod
(10h)
AstraZeneca Teases ‘Very Competitive’ Weight-Loss Pill—But Stays Mum on Details
(10h)
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
(15h)
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
(18h)
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
(1d)
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
(1d)
Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill
(1d)
Liver Toxicities Force Pause on 2 Dose Groups of UniQure’s Mid-Stage Fabry Study
(1d)
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
(1d)
2025 Reshaped the FDA. What Will 2026 Hold?
(1d)
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
(1d)
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
(1d)
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
(4d)
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
(4d)
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
(4d)
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill
(4d)
STAT News
We tested the government’s official new AI nutrition tool: Grok
(1h)
Landmark settlement could create new protections for harm reduction under disability law
(3h)
Abridge CTO on Epic and what’s after AI scribing
(3h)
TrumpRx: Hype or real savings?
(7h)
Evommune reports positive mid-stage data for eczema drug
(8h)
Trump administration revives effort to launch pilot initiative reworking drug discount program
(8h)
We’re reading about FDA rejecting a rare disease drug, a warning to a Hims compounding pharmacy and more
(8h)
Trump cabinet members watching their diets with RFK Jr.
(8h)
Eczema drug from Nektar Therapeutics maintains skin responses in one-year study
(11h)
Did the AMA change its position on surgery for transgender minors?
(13h)
Abridge CTO talks Epic, Microsoft, and rebranding as ‘more than an AI scribe’
(13h)
National Cancer Institute studying ivermectin’s ‘ability to kill cancer cells,’ alarming career scientists
(13h)
The new childhood vaccine guidelines have a paid leave problem
(13h)
Insurance companies should pay patients when they make cost-effective health care choices
(13h)
OSHU board votes to negotiate with NIH and transform its primate center into an animal sanctuary
(23h)
OHSU board votes to negotiate with NIH and transform its primate center into an animal sanctuary
(23h)
FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect
(1d)
FDA rejects Regenxbio’s rare-disease gene therapy
(1d)
The risk score shuffle, and TrumpRx’s not-so-great deals
(1d)
Hims faces mounting regulatory pressure
(1d)
BioPharma Trend
Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3
(2h)
Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic
(1d)
Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window
(5d)
Anthropic, HHMI, and Allen Institute Launch Claude-Integrated AI Collaborations for Life Science Research
(6d)
Phylo, an Agentic AI Lab, Launches with $13.5M Seed Round, Introduces Biomni Lab
(6d)
Inductive Bio Wins OpenADMET Blind Challenge With Machine Learning Models
(1w)
Beyond GLP-1: A New Combination Strategy Shows Up to 31.3% in Preclinical Study
(1w)
How Digital Health Technologies are Reshaping Clinical Development
(1w)
This AI Ready Single Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
(2w)
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
(2w)
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss
(2w)
This Company Claims World-First AI Models For Programmable Gene Insertion
(2w)
Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing
(2w)
In Another Major R&D Deal, Insilico Taps Chinese Pharma for AI-Designed Cardiometabolic Drugs
(2w)
Insilico Medicine Launches AI Gym for LLMs and Secures FDA Clearance for AI-Designed NLRP3 Inhibitor
(2w)
Neurotech Trends in 2025: When Use Cases Started Driving Design
(3w)
“ChatGPT for Doctors” Raises $250M Series D at $12B Valuation
(3w)
Tempus Launches Paige Predict Following $81M Paige AI Acquisition
(3w)
Scribe to Start First Human Trial of One-Time CRISPR Therapy for Cardiovascular Disease
(3w)
BioAge to Begin Mid-2026 Trial of Oral NLRP3 Inhibitor in Diabetic Macular Edema
(3w)
Drug Channels
Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
(12h)
In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
(4d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel
(6d)
Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending
(1w)
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2w)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(2w)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(3w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
(3w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble
(4w)
NEW: The Drug Channels 2026 Video Webinar Series
(1mo)
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
(1mo)
U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges
(1mo)
Drug Channels Leadership Forum 2026: Request an Invitation Before It’s Too Late!
(1mo)
Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026
(1mo)
340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)
(1mo)
340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth
(1mo)
Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (rerun)
(2mo)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices (rerun)
(2mo)
Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)
(2mo)
Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies (rerun)
(2mo)
European Biotechnology Magazine
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(6h)
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(7h)
4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis
(8h)
Bayer: at least success with coagulation factor XIa in phase 3 of stroke trial
(14h)
Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain
(1d)
U.K. life sciences infrastructure gets a boost as London and Cambridge expand
(1d)
SciVario® twin: One Controller for All Your Needs
(1d)
BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease
(4d)
Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week
(4d)
Novartis celebrates strong profits, while the CEO enjoys record pay triggering discussion
(4d)
Leyden Labs reports first human data for intranasal flu prevention antibody
(5d)
Pentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way also for therapeutics
(5d)
PharosAI partners with 10x Genomics on spatial cancer data backed by £18.9 million
(5d)
Cereno widens clinical program as competition heats up in lung disease
(6d)
Poxel takes first step in recovery plan with €5 million equity line
(1w)
Sartorius returns to a path of profitable growth in 2025
(1w)
Kahimmune launches and secures exclusive license for dark-genome cancer vaccine platform
(1w)
Origami and Ipsen join forces on protein degradation in neuroscience
(1w)
Sanofi ends 2025 on a high, but trims R&D priorities
(2w)
CDMOs dominate the headlines – and Lonza delivers a clear message of strength
(2w)
Drug Hunter
vimseltinib
(6h)
The New WIZ-kid in Protein Degradation
(1d)
Module 1 Quiz
(1d)
Identification Methods for Drug Repurposing: Case Studies in Neurodegeneration
(4d)
bezuclastinib (CGT9486)
(5d)
Kygevvi
(6d)
ENPP1 Inhibitors: Will Taking the Brakes off STING Help Turn up the Heat on “Cold” Tumors?
(1w)
It Takes Multiple to Mambo
(1w)
Section 4: The All-Important Dose
(1w)
lanifibranor (IVA-337)
(2w)
2025 Novel Large Molecule FDA Drug Approvals
(2w)
ADCs With Topoisomerase I Inhibitor Payloads Are Challenging Standards of Care in Oncology
(2w)
December 2025 Patent Highlights
(2w)
Hepatotoxicity Headaches: One of the Hardest Risks to De-Risk
(2w)
Section 3: Ligand Binding Basics
(2w)
2025 Molecules of the Year: Nominate!
(3w)
December 2025
(3w)
2025 Novel Small Molecule FDA Drug Approvals
(3w)
ziftomenib
(3w)
delgocitinib
(4w)
Labiotech.EU
Astellas’ “strategic brands” and “primary focuses” after XTANDI
(9h)
Breast cancer treatments heat up: Six therapies poised to transform patient outcomes
(1d)
Top biotech deals in January 2026
(4d)
How Eli Lilly’s biotech collaboration model is rewriting early-stage innovation
(4d)
The biggest biotech funding rounds in January 2026
(6d)
Nine biotech companies that could revolutionize obesity treatments
(1w)
Amarin v. Hikma: settling the skinny label question
(1w)
Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?
(2w)
Building a smart oncology pipeline with Cumulus Oncology
(2w)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(2w)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(2w)
Seven Italian biotechs to know about in 2026
(2w)
How the University of North Carolina at Chapel Hill is enhancing RNAi potency with its new technology
(2w)
A clearer path to relief: sinusitis treatments on the way
(2w)
What does 2026 hold for the biotech industry?
(3w)
Top 5 trends that will drive biopharma in the next decade with Tim Opler
(3w)
Could CRISPR really cure these diseases?
(3w)
Hepatitis B: Are we edging closer to a cure?
(3w)
From science to scale: building biotech companies via milestone leadership
(3w)
Curing ALS? Ten companies developing new treatments in 2026
(3w)
Bio IT World
Trends from the Trenches: What Lies Ahead in Bioinvestment
(17h)
The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies
(4d)
PacBio Sells Their Short-Read IP to Illumina
(1w)
Unlocking the Dangers of Disrupted Sleep
(1w)
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(2w)
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
(2w)
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
(2w)
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
(3w)
Improved Drug Safety Needs Better Data Before AI
(3w)
AI in Pharma: Progress Made, But Data Challenges Persist
(3w)
10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand
(4w)
Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch
(1mo)
PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics
(1mo)
Oxford Nanopore at JPM 2026: Passing the Baton on a 20-Year Journey
(1mo)
NVIDIA Bets Big on AI-Driven Drug Discovery, Physical AI, and a $1 Billion Eli Lilly Partnership
(4w)
TechBio Survey Shows a Mixed Industry Outlook, Claude Gaining Ground, More Machine Learning
(1mo)
Systems Biology Map for Advancing the Translation of Extracellular Vesicles
(1mo)
Insilico Medicine’s IPO, Servier Pharma Deal
(1mo)
Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization
(1mo)
Top Stories of 2025: AI for Research, Innovative Practices, Digital Twins
(1mo)
GEN News
ALS and Dementia Linked to Bacterial Sugar via Gut–Brain Axis
(1h)
How Long COVID-Related Brain Changes May Link to Alzheimer’s Disease
(2h)
Gator Bio and Hudson Lab Display Antibody Discovery Automation Solution at SLAS
(3h)
Data-Driven Strategies for Addressing Bispecific Antibody Purification Challenges
(3h)
Opentrons Uses Nvidia Tech to Build Training Data That Powers Physical AI in the Lab
(1d)
How the Flu Causes an Achy Breaky Heart
(1d)
Chimeric Small Molecule Drug Conjugate Effectively Targets Solid Tumors
(1d)
Physiological Human In Vitro Models to Study and Evaluate Tumor Immunology
(1d)
Antibiotic Resistant Genetic Elements Inactivated by CRISPR-Based Tool
(1d)
Previously Unknown Gut Bacteria Emerge as Global Marker of Health
(1d)
Takeda, Iambic Launch Up-to-$1.7B AI Collaboration
(1d)
StockWatch: Better than Expected Q4 Lifts BMS Shares
(2d)
Triple Negative Breast Cancer Cells Use ‘Sticky Coat’ to Support Clustering, Metastasis
(4d)
Cancer Outcomes Across Tumors Predicted by CCL3 Production by Neutrophils
(4d)
Multiplexing Company InDevR Acquired by SSI Diagnostica Group
(4d)
Google Cloud Survey: Life Sciences Leaders Find ROI in Agentic AI
(4d)
Norovirus Growth Breakthrough Using Mini-Gut Organoids
(5d)
New HIV Vaccine Scaffold Primes Rare B Cells for Broadly Neutralizing Responses
(5d)
Top 10 Public Mass Spectrometry Companies
(5d)
Xenotransplantation: Making Silk Purses from Sow Ears
(5d)
Cure Today
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
(1h)
From Missed Signs to Second Chances After a Liver Cancer Diagnosis
(2h)
Chris Draft Shares Steps to Help Patients Regain Control After Cancer
(3h)
Seeking a Dose of Hope Amidst Cancer
(5h)
FDA Fast Track Designation Highlights New Option in Advanced Liver Cancer
(6h)
FDA Clears Phase 2b Study of Teverelix in Advanced Prostate Cancer
(7h)
When Cancer Care Becomes a Logistical Balancing Act
(9h)
Mom of Four Shares Story of Her Breast Cancer Diagnosis
(1d)
Cancer Anniversaries Good and Bad
(1d)
A Liver Cancer Journey Marked by Persistence, Family and Hope
(1d)
Why Breast Cancer Care Isn't One Size Fits All
(1d)
Study Links Drug Therapy to Fewer Hot Flashes During Prostate Cancer Care
(1d)
FDA Grants Designation to Immunotherapy KB707 for Advanced NSCLC
(1d)
Expert Explains Adjuvant Temozolomide Boosts Astrocytoma Survival
(2d)
Radiation Oncologist and Breast Cancer Survivor Shares Her Story
(2d)
Merkel Cell Carcinoma: Explaining the Rare and Dangerous Skin Cancer
(3d)
Living with IDH-Mutant Glioma: Understanding Diagnosis, Treatment Options and Supportive Care
(3d)
Personalized Treatment Guides Lung Cancer Care for Younger Adults
(3d)
Hodgkin Lymphoma: What Should Newly Diagnosed Patients Know?
(3d)
Understanding Your Stage 3 Clear Cell Renal Cell Carcinoma Diagnosis
(3d)
Contract Pharma
Waters Completes Combination With BD Biosciences, Diagnostic Solutions Businesses
(1d)
Bruker Introduces Label-Free Characterization Platform for Nanoscale Bioparticles
(1d)
Innovent and Lilly’s Seventh Collaboration Sets Model to Accelerate Pipeline Development
(1d)
PharmaEssentia to Establish a Manufacturing Subsidiary in Puerto Rico
(1d)
Fresenius Kabi, Phlow Partner to Onshore the Manufacture of Epinephrine Injection in the U.S.
(1d)
Eurofins Viracor BioPharma Services Expands Service Portfolio
(1d)
Samsung Biologics Product Carbon Footprint System Validated by Third Party
(4d)
Proven Expertise and Customized End-to-End Solutions for Your Products
(4d)
Lilly 4Q Results
(4d)
Eisai, Henlius Strike Japan Commercialization Deal for PD‑1 Antibody Serplulimab
(4d)
FDA Grants Priority Review for Pfizer’s HYMPAVZI
(4d)
Pfizer 4Q Results
(5d)
ADARx Pharmaceuticals Appoints Donald Fong as CMO
(5d)
Braveheart Bio Promotes CSO, Names New SVP
(5d)
AbbVie Submits Regulatory Applications for Rinvoq in Patients with Vitiligo
(5d)
Novo Nordisk FY25 Results
(6d)
OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs
(6d)
Merck 4Q Results
(6d)
Biomica and Lishan Biotech Ink License Agreement for Microbiome-Based Cancer Therapeutic
(6d)
HighRes, Opentrons to Launch First AI Agent-to-Agent Lab Workflow
(6d)
Pharma Times
AstraZeneca bladder cancer therapy wins NICE backing
(12h)
Head masters
(12h)
Strong clinical data for Breye lead asset danegaptide
(1d)
EHP Awards triumph
(1d)
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
(1w)
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
(1w)
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
(1w)
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
(1w)
CERo reports encouraging early data from phase 1 trial of CER‑1236
(2w)
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
(2w)
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
(2w)
Akari files new patent and advances second ADC targeting CEACAM5
(2w)
BioMed X launches kidney disease project in partnership with the government of Barbados
(2w)
Gedeon Richter UK takes over UK rights to cariprazine
(2w)
Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
(2w)
Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
(2w)
ErVimmune raises 17m euros in funding to develop cancer vaccine
(3w)
Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
(3w)
Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
(3w)
Venner Shipley announces opening of new Bristol office
(3w)
Medcity News
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis
(1h)
Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery
(2h)
Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation
(3h)
From Pandemic Urgency to Practical Impact: How Diagnostics Investment Priorities Are Evolving
(8h)
Top ATP Tests for Effective Sanitation and Hygiene Monitoring
(8h)
The Next Stage in At-Home Healthcare is Arriving
(8h)
Take Control of Your Healthcare News: Add MedCity News to Your Google Preferred Sources
(9h)
NYU Langone Taps Isaac Health for New Virtual Dementia Care Model
(1d)
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B
(1d)
The Best EAP Providers in America: Top 10 Services for Workplace Support
(1d)
Europe’s Promising (But Rocky) Path to Embracing Single-Use Device Reprocessing
(1d)
Could AI be the Antidote to ‘Sick Care’ in America?
(1d)
Thunderstruck By OpenEvidence’s $12B Valuation? Don’t Be.
(2d)
Employers Celebrated PBM Reform. The Reality Is More Complicated
(2d)
Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer
(2d)
It Doesn’t All Have to Be Doom and Gloom for Rural Hospitals – A Blueprint for Improving Cost Structures
(2d)
Butterfly Medical Offers Non-Surgical Option to Treat Enlarged Prostate
(2d)
Medical Gap Insurance Adoption is on the Rise: Closing Coverage and Knowledge Gaps for Employers
(2d)
Why HHS Scrapping Its 340B Rebate Program Is a Win For Providers
(4d)
Chamber Secures $60M to Advance Value-Based Cardiology
(4d)
Chemical & Engineering News
EPA reapproves dicamba use, despite MAHA opposition and previous court bans
(4h)
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale
(4h)
Obituary: Lal Vishwakarma
(8h)
Obituary: Lal Vishwakarma
(8h)
Royal Society of Chemistry awards Carolyn Bertozzi Honorary Fellowship
(8h)
Chemistry in Pictures: Holey unsinkable
(9h)
Decarbonizing with a box of hot bricks
(1d)
CAS launches CAS Intelligence Hub
(1d)
Quiz: C&EN’s periodic table challenge
(1d)
Obituary: Dwain M. White
(1d)
Aromatic 5-silicon rings synthesized at last
(1d)
Iambic could earn almost $2 billion in new Takeda deal
(1d)
Artificial intelligence can spur chemical plant decarbonization
(1d)
Chemistry in Pictures: Lasers and luge sleds
(3d)
Making piezoelectrics from sugar
(4d)
Feb. 6 Policy Watch: FDA relaxes policy on food color labeling
(4d)
Seesaw device uses sunlight and gravity to extract lithium from seawater
(4d)
How chemistry helps make a highlight-reel catch
(5d)
How COVID shutdowns led to a methane surge
(5d)
Judge rules DOE climate group illegal, but lets their science stand
(5d)
The Pharma Letter
Kailera and Hengrui report ribupatide delivers 12.1% weight loss at 26 weeks
(5h)
Novo Nordisk commences legal action against Hims & Hers
(5h)
AstraZeneca’s Imfinzi wins NICE nod as first perioperative IO treatment for MIBC
(6h)
ICER releases evidence report on therapies for IgA nephropathy
(6h)
FDA accepts Takeda’s oveporexton NDA for priority review
(7h)
Moderna inks long-term deal with Mexican govt
(7h)
Gyala launches first-in-class CD84 CAR-T trial in acute leukemias
(8h)
Russia faces shortage of schizophrenia drug Latuda
(8h)
Sanofi Ventures co-leads $85 million QuantX series B
(9h)
Kainova round supports clinical advancement of GPCR-targeting therapies
(10h)
AstraZeneca delivers continued growth toward $80 billion target
(10h)
US FDA rejection sends Regenxbio shares sharply lower
(10h)
BRIEF—Astellas reaches settlement with Lupin in Myrbetriq patent litigation
(11h)
Takeda links up with Iambic on AI technology
(11h)
Pandorum Technologies raises $18 million in Series B financing
(12h)
Leadership changes at 4basebio
(12h)
AAO Annual Meeting
(13h)
VIG vow on women’s health
(1d)
Verrica announces launch of Ycanth in Japan by Torii
(1d)
Priovant to take brepocitinib into Phase III CS trial
(1d)
Targeted Oncology
Analysis Reveals Survival Gap, Racial Disparities in Ovarian Cancer Research
(5d)
Addressing the Overlooked: A New Approach to Treatment-Related High-Risk MDS
(5d)
Balancing Efficacy and Toxicity of Oral SERDs in Breast Cancer
(6d)
FDA Expands Approval of Aptima HPV Assay for Cervical Cancer Primary Screening
(6d)
MDT Boosts Survival Outcomes in Oligometastatic Prostate Cancer
(6d)
Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRC
(6d)
ADCs Could Move Up the Treatment Line in GI Cancers
(6d)
Beyond Chemo: Dr Ana Garrido-Castro on the Evolving TNBC Landscape
(6d)
Progress and Gaps in Lung Cancer Biomarker Testing at Community Centers
(6d)
Navigating the Future of CLL Care
(6d)
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
(1w)
FDA Review Restarts for Rivoceranib/Camrelizumab in Advanced HCC
(1w)
Highlighting Advances in Chondrosarcoma and TGCT Treatment
(1w)
Payload-Driven Toxicities: Clinical Red Flags in Patients Receiving ADCs
(1w)
Managing Toxicity and Safety of Belzutifan in ccRCC
(1w)
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
(1w)
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
(1w)
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
(1w)
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
(1w)
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
(1w)
MedWatch
Former FDA chief backs Novo Nordic against Hims & Hers: They've crossed the line
(8h)
AstraZeneca expects robust 2026, led by strong cancer drug demand
(10h)
BII expands beyond Denmark: Launches units in UK and Italy
(11h)
Indian drugmakers ready to pounce as Novo Nordisk's patent expiry looms
(13h)
Novo Nordisk working on response after FDA letter about misleading Wegovy ad
(13h)
Trump's new medicine platform starts with just a few drugs
(13h)
Coloplast CFO looks forward to welcoming new boss in the spring
(14h)
Gubra launches new business unit
(14h)
Hims & Hers calls Novo Nordisk's lawsuit a Danish attack on millions of Americans
(15h)
Eli Lilly acquires biotech company for billions
(15h)
Danske Bank: Bavarian Nordic could reveal cost-saving measures in upcoming annual report
(1d)
Novo Nordisk seeks to “definitively” stop Hims & Hers in new lawsuit
(1d)
Novo Nordisk profile moves to US partner Valo Health
(1d)
Analyst: Coloplast's Kerecis woes may mean downgrade
(1d)
GN CEO’s 2025 pay package exceeds competitor's by DKK 5.8m
(1d)
BioPorto appoints new CFO
(1d)
Coloplast's CEO welcomes strong growth in urology – acquisitions to support development
(1d)
Novo Nordisk received several complaints about harassment in 2025
(1d)
Several weight loss products were advertised at the Super Bowl
(1d)
Hims & Hers drops copy of Novo Nordisk's weight-loss pill days after launch
(1d)
In The Pipeline
Gumming Things Up On Purpose
(1h)
Crystals Where There Were None
(5d)
What the Literature is Filling Up With
(6d)
A Complex Cancer-Alzheimer's Connection
(7d)
The 2025 FDA Approvals
(1w)
A New LLM System for Synthesis Planning
(2w)
Rev Up The Viral Factories!
(2w)
Add Up Those Energies
(2w)
The Disastrous US Vaccine Landscape
(2w)
Microstructures All Around
(3w)
Bearing Down on a Placebo Effect
(3w)
What Makes A Drug
(3w)
Good Old Bewildering GPCRs
(4w)
Are There Accumulating Microplastics in Human Tissue or Not?
(4w)
Farewell to Dibromoethane
(4w)
mRNA Vaccines: What's the Adjuvant?
(1mo)
A Clinical Trial Nightmare
(4w)
Those Darn Viruses
(1mo)
Reversing Alzheimer's?
(1mo)
Last Year, and the Year to Come
(1mo)
Pharmaphorum
FDA kicks off review of Takeda's narcolepsy hopeful
(6h)
Kailera stakes a claim to the oral weight loss category
(8h)
Kailera, Hengrui stake claim to oral weight loss category
(8h)
AstraZeneca raises guidance on stellar cancer drugs growth
(9h)
Takeda signs $1.7bn AI alliance with Iambic
(10h)
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy
(11h)
Lupin settles Myrbetriq patent spat with Astellas for $90m
(13h)
Lilly strikes again, buying CAR-T firm Orna for $2.4bn
(1d)
Data builds on Roche's dominance in primary progressive MS
(1d)
Novartis breaks ground on San Diego biomedical R&D site
(1d)
Lilly strikes $8.8bn-plus alliance with China's Innovent
(1d)
Novo Nordisk rises as Hims & Hers backs down on oral GLP-1
(1d)
Leqembi starts to deliver for Eisai and Biogen
(4d)
Bayer reveals data behind asundexian's stroke win
(4d)
White House's TrumpRx platform has arrived
(4d)
Hims & Hers copies Novo Nordisk's new Wegovy pill
(5d)
Flagship's AI-focused Generate Biomedicines files IPO
(5d)
Amgen baulks at FDA request to withdraw Tavneos
(5d)
Grail multi-cancer test taps into Hims & Hers network
(5d)
Abbott's wireless heart failure sensor cleared for NHS use
(5d)
Drug Discovery Weekly
Charles River and Synthace to advance assay development
(6h)
Emulate showcases organ-chip platform at SLAS2026
(6h)
SLAS2026: Day One Round-Up
(9h)
DDW Highlights: 10 February 2026
(10h)
Collaboration to advance drug enhancing immunotherapy response
(11h)
Kainova secures funding to develop GPCR-targeting therapies
(12h)
US Senate reauthorises Priority Review Voucher scheme
(12h)
Global research launched into early diabetic kidney disease
(1d)
This week in Drug Discovery (2 – 6 February)
(4d)
ALTx Therapeutics launched to develop novel cancer treatments
(4d)
Beckman Coulter partners with Automata on lab automation
(4d)
CHMP recommends combination therapy to treat anal cancer
(4d)
The study of cannabinoid-based drugs: developments and opportunities
(4d)
Therapeutic approach could treat chronic low back pain
(4d)
$1.6m collaboration to advance Parkinson’s proteomics research
(5d)
Sugar-targeting antibody could kill drug-resistant bacteria
(5d)
Therapy could improve brain function in Alzheimer’s patients
(5d)
Why AI, obesity and breast cancer will dominate 2026
(5d)
From insight to impact: Catalyzing discovery at SLAS2026
(5d)
Webinar: Predict disease risk long before diagnosis
(5d)
HIT Consultant
Solace Health Raises $130M to Expand Patient Advocacy Network
(1h)
Garner Health Secures $118M to Reward Top Doctors
(1h)
Midstream Health Partners with CommonSpirit Health to Deploy AI Financial Operations Platform
(8h)
Canary Speech Partners with Intermountain Health to Study Vocal Biomarkers for Multiple Sclerosis
(8h)
The “Agent” Dilemma: How Blockchain Could Save Patient Privacy in a $500B AI Market
(9h)
The Rise of AI Triage: Navigating Regulatory Challenges and Patient Care Workflows
(15h)
Mount Sinai Study: LLMs Susceptible to Medical Misinformation in Clinical Notes
(20h)
KLAS: Why Ambulatory Practices Are Ditching Point Solutions for Epic and athenahealth
(1d)
athenahealth and b.well Launch QR-Code Intake to End Paper Forms
(1d)
How Agentic AI Optimizes HCP Marketing and ROI in Life Sciences
(1d)
The “Signage” Trap: Why Fragmented Messaging Is a Hidden Risk for Multi-Location Health Systems
(1d)
Tebra Report: 3 in 5 Staff Say ChatGPT Cuts Burnout—But 14% Admit They Can’t Function Emotionally Without It
(4d)
Accenture Federal Services Awarded 4.5-Year Contract for VA EHR Modernization
(4d)
AI in Nursing Education: Strategies for Engagement and Curriculum Data Implementation
(4d)
AI Adoption in Healthcare Doubles, But Cybersecurity Risks Loom Large
(4d)
Vivos Therapeutics to Distribute SoundHealth’s FDA-Cleared Sonu and Spatial Sleep Bands
(4d)
Opentrons and NVIDIA Partner to Develop Physical AI for Laboratory Robotics
(4d)
Sword Intelligence Launches in UK and Europe with AI-Led Care Operations Platform
(4d)
Healthcare Outsourcing Philippines: The 7-Stage Supplier Selection Process That Protects Both Revenue and Patient Data
(4d)
TrumpRx.gov Launches with 80% Discounts on Ozempic and Wegovy
(5d)
Insights: Pink Sheet
Sobi Takes Second Shot At EU Gamifant Approval
(2h)
Potential Blockbusters From AstraZeneca And Lilly Now Under EMA Review
(2h)
GLP-1s Likely TrumpRx Savings Focus Over Old, Genericized Products
(4h)
EMA Backs Smarter Tool To Spot Pregnancy‑Related Medicine Risks
(8h)
Pharma Hit With $755m In False Claims Act Recoveries
(1d)
US FDA Compassionate Use Reviews ‘Not Affected’ By Trump Policies
(1d)
US FDA Flags Launch Ad For Novo Nordisk’s Wegovy Pill; Is Super Bowl Commercial Next?
(1d)
EU CHMP Opinions And MAA Updates
(1d)
EU AI Act Could ‘Set Back’ Benefits Of AI In Drug Development If Applied To RD
(1d)
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched
(3d)
Hims & Hers’ Compounded Semaglutide Pill Triggers US FDA Enforcement
(4d)
Citizen Pazdur: Former US FDA Oncology Head Still Interested In Drug Development
(4d)
Cardio-Renal-Metabolic Drugs Face World Made By GLP-1s, Juiced By National Priority Vouchers
(4d)
Pink Sheet Podcast: US FDA Hiring Improves, But Can The Agency Avoid Oversight Erosion?
(4d)
UK Clinical Trials Stumbling On NHS ‘Delivery Friction’
(4d)
Global Pharma Guidance Tracker – January 2026
(4d)
TrumpRx Launch Highlights MFN Drug Discounts, With Caveats
(4d)
India Non-Animal Testing Methods: Outlook And Near-Term Opportunities
(4d)
Eli Lilly Predicts Medicare Coverage Of Zepbound Will Draw Current DTC Customers
(5d)
GDUFA IV: US FDA Seeks To Codify Domestic Manufacturing ANDA Prioritization Pilot
(5d)
BioXconomy
Experts unveil AI breakthroughs in streamlining regulatory reviews
(5h)
Capsida confirms cause of death in clinical trial fatality for rare genetic disorder
(9h)
Lilly to buy Orna in CAR T deal worth up to $2.4bn
(10h)
Viatris, Septerna, BIO, Takeda name new legal chiefs
(11h)
Generate Biomedicines targets IPO to advance asthma treatment
(13h)
Pharmaceutical companies require robust internal audit systems to prepare for FDA inspections
(1d)
From isolation to integration: Redefining ethics and compliance in the data-driven era
(1d)
Medable launches AI agent to help with trial outcome assessment
(1d)
UAE partners with Colossal Biosciences to lead global conservation efforts
(1d)
Dual-targeting siRNAs could treat more complex genetic diseases
(4d)
Kim Boericke takes the helm as Veristat CEO: Driving innovation, diversity, and patient-centric growth in life sciences
(4d)
Eikon goes public with $381m to advance cancer therapies
(4d)
Investigator-led studies drive China’s early-phase trials boom
(5d)
Santé Ventures raises $330m to invest in ‘innovative biotechnology
(5d)
Which drugs will be picked for Medicare negotiation in 2026?
(6d)
Proposed Biotech Act would help EU win more trials, says EMA
(6d)
Weight loss with a single injection? Fractyl Health is taking that bet.
(6d)
ICON expands Accellacare network with Chicago cancer research institute
(1w)
Eyes on Asia: SangeneBio, Newsoara, AstraZeneca
(1w)
WHO recommends ‘long-term treatment for obesity’ with GLP-1s in first-ever guidelines
(1w)
BioCentury
Start-up funding, the perils of compounding, and neuropsych insights — a BioCentury podcast
(21h)
Galux: Scaling AI-designed biologics
(22h)
The next wave of biotech growth — a Perspective
(1d)
Lilly buys Orna, strikes broad pipeline deal with Innovent: Deals Report
(1d)
McKinsey vet Franck Le Deu joins Nisa Leung’s new fund; plus C-suite shuffle at Bicycle
(3d)
Series A companies: Biotech’s class of 2025
(3d)
Compounded Wegovy is more than a scam — it threatens innovation
(4d)
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report
(4d)
Sanofi misses in Fabry: Is it time to move on from GCS inhibition in the indication?
(4d)
Latent Labs: AI-designed, ready-to-develop biologics
(4d)
Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul
(4d)
Angitia’s latest megaround to fuel mid-stage milestones: Venture Report
(5d)
Dialing out the hallucinogenic effect of psychedelics — BioCentury’s Science Spotlight
(6d)
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue
(6d)
Even endpoint hits don’t spare shares in three weight-loss updates
(6d)
Rep. Auchincloss challenges legality of commissioner’s national priority voucher program
(7d)
Obesity data weigh on Pfizer shares, but growing pipeline has multiple catalysts
(7d)
Spending law a rebuke to proposed White House biomedical cuts
(1w)
Biotech’s 2026 Catalysts. Plus: China’s New Orphan Rules — a BioCentury podcast
(1w)
Wave, Kyowa Kirin to advance programs after partners bow out: Deals Report
(1w)
SCRIP
Evommune’s Atopic Dermatitis Data Competitive With Dupixent
(34m)
CSL CEO Paul McKenzie Exits With Former Exec Gordon Naylor Stepping In
(4h)
FDA Delivers Regenxbio Another Blow, This Time for RGX-121
(4h)
Aerska Builds Cashpile To Advance Brain Shuttle Tech
(6h)
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity
(7h)
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Has Directed Mediation
(13h)
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Directed Mirabegron Mediation
(13h)
Stock Watch: Pfizer Navigates Vaccine Gains And Acquisition Pains
(13h)
TrumpRx May Be New, But It Showcases Pharma’s Age
(1d)
Insmed Plots Its Course For A Long Growth Journey
(1d)
Novo Nordisk Sues Hims & Hers Over Semaglutide Pill, HHS Seeks Criminal Investigation
(1d)
Finance Watch: Santé Ventures Closes $330m Fund, While Gimv Ends Life Science Investments
(1d)
Nanobiotix: On Cusp Of A Breakthrough With J&J-Partnered Radioenhancer Tech
(1d)
Lilly Joins The In Vivo Cell Therapy Fray With Orna Acquisition
(1d)
A Look At The Next Gen Obesity Pipeline Coming Out Of China
(1d)
Innovent, Lilly Partner On Oncology, Immunology Programs
(1d)
Quick Listen: Scrip’s Five Must-Know Things
(1d)
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched - Clone
(3d)
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched
(3d)
TrumpRx Launch Highlights MFN Drug Discounts, With Caveats
(4d)